The newly unveiled Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has proposed salivary gland neoplasm of uncertain malignant potential (SUMP) as an indeterminate category. The category is reserved for fine-needle aspiration (FNA) cases that are diagnostic of a salivary gland neoplasm but cannot be further designated as a specific tumor type. The objective of the current study was to evaluate the clinical utility of subtyping SUMP cases based on different cell types. METHODS: A retrospective search of cytology databases at 2 institutions for salivary gland 
INTRODUCTION
Salivary gland fine-needle aspiration (FNA) is among the most challenging fields in diagnostic cytopathology. The wide morphologic spectrum of salivary gland cytology reflects the complexity of salivary gland pathology. There are various types of tumors in the salivary glands. The newly updated 2017 World Health Organization classification has listed more than 30 types of benign and malignant salivary gland epithelial tumors, in addition to other tumors of hematopoietic or soft-tissue origins. 1 The morphologic heterogeneity may occur in a single tumor type because of tumor differentiation, metaplasia, tissue change, or reaction. For example, it is not uncommon to observe squamous metaplasia or cystic change in a pleomorphic
Cancer Cytopathology November 2018 adenoma, which causes diagnostic confusions. [2] [3] [4] [5] Moreover, even a single cell type can present with diverse cytomorphology. For instance, myoepithelial cells can be spindle-shaped, epithelioid, plasmacytoid, or even clear. 6 In addition, non-neoplastic, tumor-like salivary gland lesions as well as other primary tumors occurring in lymph node, soft tissue, or skin adjacent to the salivary glands can clinically mimic a salivary gland tumor for FNA evaluation. 7 Therefore, although a specific cytologic diagnosis is not difficult in many common salivary gland tumors, rare tumor types, selective sampling, or misleading anatomic locations of FNA can sometimes lead to major misdiagnoses. [8] [9] [10] The objective of the recently unveiled Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is to provide an internationally recognized, uniform reporting system with standardized terminology to replace the conventional, descriptive interpretation for salivary gland FNA. 11 The 7-tiered classification includes nondiagnostic (MSRSGC category I), non-neoplastic (category II), atypia of undetermined significance (AUS) (category III), benign neoplasm (category IVa), salivary gland neoplasm of uncertain malignant potential (SUMP) (category IVb), suspicious for malignancy (category V), and malignant (category VI). 12 The SUMP category is reserved for a small but heterogeneous group of cases with cytomorphologic features diagnostic of a neoplasm but indefinitive for a specific tumor type to further distinguish between benign or malignant. In our experience, a majority of the most formidable salivary gland FNA cases will now be classified under this indeterminate diagnostic category. However, the varied histologic follow-up in this group may cause uncertainty in clinical management. The objectives of the current study were to better characterize SUMP cases by subtyping them based on different cell type and to evaluate the clinical utility of this practice.
MATERIALS AND METHODS

Case Selection
The study was approved by the institutional review boards ( (Fig. 3) . The myoepithelial subtype applies to 2 circumstances. First, it can be used for cases that exhibit the classic features of benign pleomorphic adenoma, whereas focal cellular atypia is conspicuous (Fig. 4A,B) . In this situation, the differential diagnosis is benign pleomorphic adenoma with focal atypia versus noninvasive or invasive carcinoma ex pleomorphic adenoma. For the second situation, the Cancer Cytopathology November 2018
cases are composed predominantly of myoepithelial cells (Fig. 4C,D) . The main differential diagnosis is cellular pleomorphic adenoma versus myoepithelioma or myoepithelial carcinoma.
Statistical Analyses
Data were summarized using descriptive statistics. Means and ranges were used for continuous variables, whereas counts and frequencies were used for categorical variables. Fisher exact tests were performed to compare proportions of categorical variables. Analyses of variance were performed to test for differences among means of multiple groups. Two-sided P values < .05 were considered statistically significant. Statistical analyses were performed using the R software package (version 3.5.0; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Reclassification of the Study Cohort
In total, 1560 salivary gland aspirates was identified (675 from Taipei Veterans General Hospital and 885 from Indiana University) from the 12-year study period. Table 1 .
Clinical Characteristics of SUMP and Subtypes
Among the 59 patients who had an FNA diagnosis of SUMP and available histologic follow-up, there were 23 men and 36 women with a mean age of 56.3 years (range, Cancer Cytopathology November 2018
17-91 years). Fifty-two nodules were from parotid glands, and 7 were from submandibular glands. The mean nodule size was 2.2 cm (range, 0.7-9.4 cm). After slide review, the 59 aspirates of SUMP were designated to subtypes based on cell type. There were 18 cases (30.5%) of the oncocytic/squamoid subtype, 25 cases (42.4%) of the basaloid subtype, and 16 cases (27.1%) of the myoepithelial subtype. For the myoepithelial subtype, 12 cases had cellular myoepithelial aspirates, and 4 had focal atypia. Ancillary testing was not applied in any cases. The clinical characteristics are summarized in Table 2 . There were no significant differences noted with regard to clinical features among patients who had different SUMP subtypes, except sex (P = .0379), of which women were more prevalent in the patients with the myoepithelial subtype.
Pathologic Correlation and ROM for Different SUMP Subtypes
The follow-up pathologic diagnoses for each SUMP subtype are listed in Table 3 . Overall, 57 of 59 of FNAs (96.6%) that were diagnosed as SUMP were neoplastic.
For the oncocytic/squamoid subtype, the most common pathology was mucoepidermoid carcinoma (7 of 18 FNAs; 38.9%) and Warthin tumor (3 of 18 FNAs; 16.7%). It is worth noting that the only 2 non-neoplastic lesions (1 salivary duct cyst and 1 chronic sialoadenitis) were both classified as this subtype. For the basaloid subtype, the most common pathology was basal cell adenoma (10 of 24; 41.7% FNAs), followed by pleomorphic adenoma (5 of 24 FNAs; 20.8%), and adenoid cystic carcinoma (4 of 24 FNAs; 16.7%). For the myoepithelial subtype, the most common pathology was pleomorphic adenoma (11 of 17 FNAs; 64.7%). The ROM for each SUMP subtype is provided in Table 4 . The ROM was highest for the oncocytic/squamoid subtype (11 of 18 FNAs; 61.1%), followed by the basaloid subtype (10 of 25 FNAs; 40.0%), and the myoepithelial subtype (3 of 16 FNAs; 18.8%). The differences in ROM among all 3 subtypes were statistically significant (P = .0476). For the comparison of ROM between 2 subtypes, the ROM of oncocytic/squamoid SUMP was substantially higher than that of myoepithelial SUMP Cancer Cytopathology November 2018 (P = .0173), whereas both oncocytic/squamoid versus basaloid (P = .2231) and basaloid versus myoepithelial comparisons were statistically insignificant (P = .1874). Although the ROM of the myoepithelial subtype was the lowest among all SUMPs, it was still significantly higher than the ROM of the benign neoplasm category (18.8% vs 2.9%; P = .016) DISCUSSION FNA cytology is widely used for the evaluation of salivary gland nodules. It demonstrates high specificity in the diagnosis of some common benign epithelial neoplasms, such as pleomorphic adenoma and Warthin tumor, 13 as well as frankly malignant, high-grade neoplasms. 14, 15 However, it can be challenging to distinguish between a benign and a bland-looking, low-grade to intermediate-grade malignant tumor because of cytomorphologic overlap and diversity. [7] [8] [9] [10] For that reason, the MSRSGC has proposed SUMP as an indeterminate diagnostic category. 12 This category is reserved for FNA cases that are diagnostic of a neoplasm but in which the possibility of a malignant neoplasm cannot be excluded. Previous literature has suggested various approaches to the cytologic evaluation of these indeterminate neoplastic lesions. Some have illustrated a simple scheme by separating these into 2 groups as basaloid neoplasm and salivary gland neoplasm with predominant oncocytic cells, 16 whereas others have developed a more sophisticated approach that takes into consideration cell type (basaloid or oncocytoid), variation of nuclear size (pleomorphic or monomorphic), stroma (fibrillary, hyaline, or mixed), background materials (cystic, mucinous, or other), and cytoplasmic features (granular/vacuolated). 17 The MSRSGC has recommended 3 subcategories for SUMP: namely, cellular basaloid neoplasm, cellular oncocytic/ oncocytoid neoplasm, and cellular neoplasm with clearcell features. 18 In the current study, we subtyped SUMP cases based on 3 different cell types to comprise most of the diagnostic scenarios for indeterminate salivary gland FNA cases according to our own experience. The rationale was to focus on the differential diagnoses associated with the 3 most common benign salivary gland neoplasms-Warthin tumor, basal cell adenoma, and pleomorphic adenoma-by separating these cases into oncocytic/squamoid, basaloid, and myoepithelial subtypes, respectively. Then, we examined the histologic follow-up and analyzed the ROM for each subtype to evaluate the clinical utility of this practice. The oncocytic/squamoid subtype is characterized by neoplastic epithelial cells with moderate-to-abundant amounts of granular or dense cytoplasm. The diagnosis of benign oncocytic tumors, such as Warthin tumor or oncocytoma/oncocytosis, is usually not difficult. In occasional cases, however, the presence of atypical features Cancer Cytopathology November 2018
(eg, squamous metaplasia, mucinous metaplasia, or mucoid background materials) will raise concern of a lowgrade mucoepidermoid carcinoma. 19 Conversely, when a mucoepidermoid carcinoma exhibits oncocytoid change, cystic debris, or prominent lymphocytic infiltrates, it may overlap with the cytomorphologic features of a benign Warthin tumor. 20 The histologic follow-up for the oncocytic/squamoid subtype in the current study revealed 7 mucoepidermoid carcinomas (Fig. 1A,D) , 3 Warthin tumors ( Fig. 2A,B) , and 1 oncocytoma (Fig. 2C,D) . These tumors comprised 11 of 18 cases (61.1%). Although cellular neoplasm with clear-cell features is proposed by the MSRSGC as a SUMP subcategory, we observe wide cytomorphologic overlap with oncocytic/squamoid subtype cases. Clear-cell features are generally an artifactual phenomenon in histology because of formalin fixation. The corresponding cytomorphologic features represent granular, foamy, or vacuolated cytoplasm, other than clear. The differential diagnoses are seldom benign but rather are restricted in some less common malignant tumors, such as acinic cell carcinoma, 21 secretory carcinoma, 22, 23 hyalinizing clear-cell carcinoma, 24 clear-cell myoepithelial carcinoma, 25 rare cellular changes of mucoepidermoid carcinoma, 26 or metastasis. 27 If a specific diagnosis cannot be ascertained, then this group of tumors may be better classified as suspicious for malignancy. In the oncocytic/squamoid subtype of SUMP, we accepted rare cases that exhibited abundant foamy or vacuolated cytoplasm as a spectrum of oncocytoid cells. Histologic follow-up identified 1 acinic cell carcinoma (Fig. 1B,E ) and 1 secretory carcinoma (Fig. 1C,F) . Other pathology included a salivary duct carcinoma exhibiting scant atypical cells with apocrine features that mimicked oncocytes; a pilomatrixoma presenting as a parotid mass and exhibiting scant atypical squamoid cells; a non-neoplastic cyst containing an abundant, mucoid background and scant epithelial cells, simulating a mucoepidermoid carcinoma; and 2 lymphoepithelial lesions (1 chronic sialoadenitis and 1 extranodal marginal zone B-cell lymphoma) resembling Warthin tumors. Overall, the ROM of the oncocytic/squamoid subtype was the highest in this study (61.1%), suggesting that surgical management should be highly recommended. The basaloid subtype represents cases exhibiting epithelial tumor cells with scant cytoplasm. The cells are often associated with sharply marginated, hyaline-type extracellular matrix, which is better demonstrated by Romanowsky-type stain. Differentiating between benign versus malignant tumors with basaloid features is a diagnostic challenge and sometimes is impossible because of overlapping cytomorphology. 16, [28] [29] [30] In addition, certain types of extracellular matrix are nonspecific for the diagnosis and sometimes misleading. Hyaline globules surrounded by basaloid cells are a characteristic feature of adenoid cystic carcinoma. However, this feature has been noted in benign basal cell adenoma (Fig. 3C,D) , pleomorphic adenoma, and myoepithelioma, and this may lead to false-positive diagnoses. 2, 3, [28] [29] [30] Hyaline globules also have been observed in other malignant tumors like epithelial-myoepithelial carcinoma and polymorphous adenocarcinoma of minor salivary glands. 31, 32 Membranous-type hyaline matrix wrapping around basaloid cell clusters is a common feature of basal cell adenoma. 30 Although less described in the literature, this feature also may present in an adenoid cystic carcinoma with predominant tubular pattern (Fig. 3A,B) , causing a false-negative diagnosis. Therefore, the SUMP category is recommended for basaloid neoplasms without Benign pathology Warthin tumor, n = 3 Basal cell adenoma, n = 10 Pleomorphic adenoma, n = 11 Oncocytoma, n = 1
Pleomorphic adenoma, n = 5 Basal cell adenoma, n = 1 Pilomatrixoma, n = 1 Myoepithelioma, n = 1 Salivary duct cyst, n = 1 Chronic sialadenitis, n = 1 Malignant pathology Mucoepidermoid carcinoma, n = 7
Adenoid cystic carcinoma, n = 4 Adenoid cystic carcinoma, n = 1 Acinic cell carcinoma, n = 1
Epithelial-myoepithelial carcinoma, n = 2 Carcinoma ex pleomorphic adenoma, n = 1 Secretory carcinoma, n = 1
Metastatic basaloid squamous cell carcinoma, n = 2 Myoepithelial carcinoma, n = 1 Salivary duct carcinoma, n = 1 Carcinoma ex pleomorphic adenoma, n = 1 MALT lymphoma, n = 1 Salivary duct carcinoma, n = 1 Abbreviation: MALT, mucosa-associated lymphoid tissue.
Cancer Cytopathology November 2018 unequivocal cytologic features of carcinoma to avoid diagnostic discrepancy. A definite diagnosis should not be based on types of extracellular matrix alone for these tumors. In the current study, histologic follow-up for the basaloid subtype revealed 10 basal cell adenomas, 6 pleomorphic adenomas (including 1 carcinoma ex pleomorphic adenomas), 4 adenoid cystic carcinomas, and 2 epithelial-myoepithelial carcinomas. These tumors comprised 88% (22 of 25) of the cases. The overall ROM of the basaloid subtype was 40%, which fell between the other 2 subtypes.
The myoepithelial subtype is reserved for tumors of myoepithelial differentiation that exhibit indeterminate atypical features. The first scenario for this subtype is when focal questionable atypia is present in cases that otherwise exhibit characteristic features of pleomorphic adenoma. Pleomorphic adenoma is the most common benign salivary gland neoplasm. Nevertheless, carcinomas occasionally may arise from pleomorphic adenomas and exhibit aggressive behavior. Selective FNA sampling of carcinoma ex pleomorphic adenoma may cause a false-negative diagnosis. In previous studies, only 29% to 50% of cases had a preoperative FNA diagnosis of malignancy. [33] [34] [35] [36] Conversely, various degrees of cellular atypia are not uncommon in benign pleomorphic adenomas and may be overcalled as malignant. 2, 3, 8 In the current study, there was 1 carcinoma ex pleomorphic adenoma of the 4 myoepithelial subtype cases of focal atypia on histologic follow-up. The other 3 were all benign pleomorphic adenoma (Fig. 4A,B) . The second scenario applies to cases composed of predominately myoepithelial cells. The myoepithelial cells are often plasmacytoid with diffuse, mild-to-moderate atypia (Fig. 4C,D) . The extracellular stroma may be present but usually is not chondromyxoid in texture. The main differential diagnosis has included cellular pleomorphic adenoma, myoepithelioma, basal cell neoplasm, and myoepithelial carcinoma. 6, 29 In the current study, the histologic follow-up for cellular myoepithelial aspirates revealed 11 pleomorphic adenomas, 1 basal cell adenoma, 1 myoepithelial carcinoma, and 1 adenoid cystic carcinoma. Overall, the ROM for the myoepithelial subtype of SUMP was the lowest. Recent molecular advances reveal several typespecific genetic alterations in salivary gland tumors. 37 Ancillary testing, such as immunocytochemistry, fluorescence in situ hybridization, or polymerase chain reaction, has emerged and has been used increasingly in cytopathology. 32, 38, 39 Nonetheless, more studies are still required to validate the performance of these tests on cytologic specimens. Because complete surgical excision is the standard treatment for most symptomatic salivary gland tumors, FNA confirmation of a neoplastic lesion is sufficient for subsequent clinical management. A type-specific diagnosis seldom changes the procedure. From a practical point of view, imaging evaluation of the tumor border may provide further information regarding the extent of surgery. 40 In conclusion, SUMP is a robust diagnostic category that comprised 5.9% of the total salivary gland FNA cases in this 12-year retrospective review. Among them, 96.6% had confirmed neoplastic diagnoses upon follow-up. Subtyping SUMP cases demonstrated differential ROMs for the oncocytic/squamoid (61.1%), basaloid (40.0%), and myoepithelial (18.8%) subtypes (P = .0476). This simple and practical approach facilitates 
